Baxter International Inc.(BAX) Stock Research - Grey Stern Research

Baxter International Inc. (BAX) Stock Analysis

$33.19 (-0.75%)

BAX Financial Performance


Use the table below to view Baxter International Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2024

Metric Value Ranking among Peers
Price $33.44 -
52 Week Low $28.34 -
52 Week High $43.99 -
Market Cap $17.1 Billion 3/11
Gross Margin 35% 11/11
Profit Margin -19% 11/11
EBITDA margin -6% 11/11
Q4 - 2024 Revenue $2.8 Billion 2/11
Q4 - 2024 Earnings -$512.0 Million 11/11
Q4 - 2024 Free Cash Flow $351.0 Million 2/11
Trailing 4 Quarters Revenue $12.9 Billion 2/11
Trailing 4 Quarters Earnings -$649.0 Million 10/11
Quarterly Earnings Growth -309% 10/11
Annual Earnings Growth -108% 9/11
Quarterly Revenue Growth -29% 10/11
Annual Revenue Growth -14% 10/11
Cash On Hand $1.8 Billion 2/11
Short Term Debt $2.8 Billion 1/11
Long Term Debt $10.6 Billion 2/11

Baxter International Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Baxter International Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 9/11
PS 1.33 9/11
PB 2.44 6/11
PC 9.70 8/11
Liabilities to Equity 2.69 1/11
ROA -0.03 9/11
ROE -0.09 10/11
Current Ratio 1.37 10/11
Quick Ratio 0.09 9/11
Long Term Debt to Equity 1.52 1/11
Debt to Equity 1.93 1/11
Burn Rate 1.07 6/11
Cash to Cap 0.10 4/11
CCR -0.69 8/11
EV to EBITDA -163.60 10/11
EV to Revenue 2.24 8/11

Company Details

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

CEO: Mr. Jose Almeida

Website: https://www.baxter.com

Address: 1 Baxter Pkwy Deerfield, ILLINOIS

Exchange: New York Stock Exchange

Industry: Medical Instruments & Supplies

Baxter International Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Baxter International Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Becton, Dickinson and Company BDX $66.1 Billion
Hologic, Inc. HOLX $13.8 Billion
ResMed Inc. RMD $32.3 Billion
The Cooper Companies, Inc. COO $16.3 Billion
Teleflex Incorporated TFX $6.6 Billion
West Pharmaceutical Services, Inc. WST $16.5 Billion
Merit Medical Systems, Inc. MMSI $6.0 Billion
ICU Medical, Inc. ICUI $3.6 Billion
Envista Holdings Corporation NVST $2.9 Billion
Embecta Corp. EMBC $745.3 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
BAX Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 2.8 Billion -$512.0 Million
Q3 2024 $ 2.7 Billion $140.0 Million
Q2 2024 $ 3.8 Billion -$314.0 Million
Q1 2024 $ 3.6 Billion $37.0 Million
Q4 2023 $ 3.9 Billion $245.0 Million
Q3 2023 $ 3.7 Billion $2.5 Billion
Q2 2023 $ 3.7 Billion -$141.0 Million
Q1 2023 $ 3.6 Billion $44.0 Million

View All

BAX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $1.8 Billion $25.8 Billion $13.4 Billion $7.0 Billion
Q3 2024 $1.4 Billion $26.7 Billion $13.2 Billion $7.9 Billion
Q2 2024 $2.1 Billion $26.3 Billion $13.3 Billion $7.7 Billion
Q1 2024 $3.0 Billion $27.8 Billion $14.2 Billion $8.2 Billion
Q4 2023 $3.2 Billion $28.3 Billion $14.4 Billion $8.5 Billion
Q3 2023 $5.8 Billion $30.7 Billion $16.9 Billion $8.2 Billion
Q2 2023 $1.7 Billion $27.9 Billion $16.9 Billion $5.6 Billion
Q1 2023 $1.7 Billion $28.3 Billion $16.9 Billion $5.9 Billion

View All

BAX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2024 $351.0 Million -$137.0 Million $334.0 Million
Q3 2024 -$300.0 Million -$22.0 Million -$16.0 Million
Q2 2024 -$1.0 Million -$116.0 Million -$931.0 Million
Q1 2024 -$13.0 Million -$176.0 Million -$172.0 Million
Q4 2023 $341.0 Million -$190.0 Million -$2.6 Billion
Q3 2023 $2.0 Million $0 $2.0 Million
Q2 2023 $195.0 Million -$156.0 Million $49.0 Million
Q1 2023 $307.0 Million -$172.0 Million -$45.0 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions